| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.0091 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |